Home Antibody All anti-TNFSF11 antibodies
Also for TNFSF11 (NM_003701)
|sRANK-L antibody was raised against a 14 amino acid peptide from near the center of human sRANK-L .|
|Human, Mouse, Rat
||WB: 0.25 - 0.5 ug/ml
|PBS containing 0.02% sodium azide.|
|Affinity chromatography purified via peptide column
|Homo sapiens tumor necrosis factor (ligand) superfamily, member 11 (TNFSF11), transcript variant 1|
|CD254; hRANKL2; ODF; OPGL; OPTB2; RANKL; sOdf; TRANCE|
|The receptor activator of NF-kappaB ligand (RANK-L) is a recently discovered member of the TNF-ligand family involved in the regulation of the T cell-dependent immune response, lymph node organogenesis and bone formation. RANK-L exists as both a normal, transmembrane form and a truncated, soluble form (sRANK-L), both of which can stimulate the receptor. Activation of T cells, such as by treatment with interleukin-7, induces RANK-L production and leads to an increase of osteoclast formation and bone loss. Finally, sRANK-L can activate the antiapoptotic kinase Akt through a signaling complex involving Src kinase and TRAF6, suggesting sRANK-L may also play a role in regulating apoptosis. This antibody will recognize both the soluble form and the uncleaved transmembrane form of RANK-L.|
Cytokine-cytokine receptor interaction
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis of sRANK-L in rat liver tissue lysate with sRANK-L antibody at (A) 0.25 and (B) 0.5 ug/ml.
Immunohistochemistry of sRANK-L in human liver tissue with sRANK-L antibody at 5 ug/ml.